NCT03485092View on ClinicalTrials.gov

Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects

PHASE4CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

March 16, 2018

Primary Completion Date

March 28, 2020

Study Completion Date

March 28, 2020

Conditions
Heart FailureDiabetes Mellitus
Interventions
DRUG

Empagliflozin 10 MG

Empagliflozin 10mg tablets for oral self administration once a day

DRUG

Placebo Oral Tablet

placebo tablets for oral self administration once a day

Trial Locations (1)

G51 4TF

Queen Elizabeth University Hospital, Glasgow

All Listed Sponsors
collaborator

University of Glasgow

OTHER

lead

NHS Greater Glasgow and Clyde

OTHER

NCT03485092 - Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects | Biotech Hunter | Biotech Hunter